5 results
The primary objective is to evaluate the safety of ReFacto AF in previously untreated patients (no prior exposure to factor products or any blood products) of less than 6 years of age.
The primary objective of the study is to evaluate the feasibility of 89Zr-bevacizumab PET imaging as a biomarker before and during treatment with everolimus in patients with metastatic RCC. 89Zr-bevacizumab PET imaging will be regarded a promising…
To compare the methods patients will be divided into two groups, a therapy group (receiving cTreatment) and a control group (receiving standard cryotherapy). Patients will be evaluated pre- and postoperatively, wherefore the following data are…
The primary objective is to determine if disease associated lesions in patients with VHLD can be visualized with 89Zr-bevacizumab PET scans. Secondary objectives are to explore if 89Zr-bevacizumab PET imaging can differentiate progressive from non-…
In the present study, we aim to perform a feasibility study to prove that 89Zirconium-bevacizumab PET scanning can indeed detect all small primary breast cancer lesions. Data from the present study may be used to design further studies with regard…